OrganOx gets £25M for its transportable, automated ex vivo liver perfusion device

The proceeds will enable OrganOx to significantly expand its commercial footprint across strategically key areas of the business. This includes expanding the customer-facing team in the United States due to high interest and adoption of the OrganOx technology. In addition, the investment will be made in new infrastructure to facilitate and accelerate programs within the R&D pipeline.